FO supplementation has been shown to: reduce malignant epithelial cell proliferation (Ki67) marker in prostate cancer; reverse cachexia in advanced pancreatic cancer; maintain patient weight and muscle mass during chemotherapy in lung cancer; improve liver and pancreas function in postoperative patients with abdominal cancer; and increase chemotherapeutic efficacy (without affecting the toxicity profile) and survival in patients with lung cancer [5–8, 19]. The gene discussed is MKI67; the disease is prostate carcinoma.